Literature DB >> 27719637

Targeting Notch as a Therapeutic Approach for Human Malignancies.

Natalia Platonova1, Elena Lesma2,3, Andrea Basile2,3, Monica Bignotto2,3, Silvia Garavelli2, Maria Teresa Palano2, Adriana Moschini2, Antonino Neri1,4, Michela Colombo2, Raffaella Chiaramonte2,3.   

Abstract

BACKGROUND: Notch is a multifaceted protein that plays a fundamental role in fetal development and tissue homeostasis by directing many cellular functions, including cell growth and differentiation, cell fate determination and regulation of stem cells maintenance. The Notch family consists of four receptors (Notch 1-4) and five ligands (Jagged1-2 and Delta-like 1-3-4) widely expressed in human tissues. Given the crucial contribution of Notch signaling in many physiological processes, it is not surprising that a variety of human malignancies is characterized by a dysregulation of one or more components of this pathway.
METHODS: In this review, we are going to provide a broad overview on the role of Notch pathway in solid and hematological malignancies and a survey on possible Notch-directed therapeutic strategies.
RESULTS: We present the most recent findings indicating that Notch signaling dysregulation in human cancers may be due to genetic and epigenetic alterations or to the interactions with other oncogenic pathways. Furthermore, Notch activity may have an oncogenic or a tumor suppressor effect. Finally, we describe the latest preclinical and clinical studies concerning the different pharmacological approaches targeting Notch.
CONCLUSION: The provided evidence confirms the importance of Notch pathway in human malignancies indicating that a strong rationale exists for the development of a Notch-tailored therapy. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Dll; Jagged; Notch; apoptosis; clinical trial; proliferation; therapeutic target

Mesh:

Substances:

Year:  2017        PMID: 27719637     DOI: 10.2174/1381612822666161006160524

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  10 in total

1.  Co-Expression Analysis Reveals Mechanisms Underlying the Varied Roles of NOTCH1 in NSCLC.

Authors:  Sara L Sinicropi-Yao; Joseph M Amann; David Lopez Y Lopez; Ferdinando Cerciello; Kevin R Coombes; David P Carbone
Journal:  J Thorac Oncol       Date:  2018-11-05       Impact factor: 15.609

2.  Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia.

Authors:  Dan Li; Tongjuan Li; Zhen Shang; Lei Zhao; Qian Xu; Jiaqi Tan; Yun Qin; Yuanyuan Zhang; Yang Cao; Na Wang; Liang Huang; Xiaojian Zhu; Kuangguo Zhou; Liting Chen; Chunrui Li; Ting Xie; Yi Yang; Jue Wang; Jianfeng Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-03-13

Review 3.  Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.

Authors:  Paulina Kozakiewicz; Ludmiła Grzybowska-Szatkowska
Journal:  Oncol Lett       Date:  2018-03-20       Impact factor: 2.967

4.  Identification of small molecules uncoupling the Notch::Jagged interaction through an integrated high-throughput screening.

Authors:  Natalia Platonova; Chiara Parravicini; Cristina Sensi; Alessandro Paoli; Michela Colombo; Antonino Neri; Ivano Eberini; Raffaella Chiaramonte
Journal:  PLoS One       Date:  2017-11-03       Impact factor: 3.240

Review 5.  Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu.

Authors:  Michela Colombo; Leonardo Mirandola; Maurizio Chiriva-Internati; Andrea Basile; Massimo Locati; Elena Lesma; Raffaella Chiaramonte; Natalia Platonova
Journal:  Front Immunol       Date:  2018-08-14       Impact factor: 7.561

6.  Dissecting molecular mechanisms of resistance to NOTCH1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts.

Authors:  Valentina Agnusdei; Sonia Minuzzo; Marica Pinazza; Alessandra Gasparini; Laura Pezzè; Adriana Agnese Amaro; Lorenza Pasqualini; Paola Del Bianco; Martina Tognon; Chiara Frasson; Pietro Palumbo; Yari Ciribilli; Ulrich Pfeffer; Massimo Carella; Alberto Amadori; Stefano Indraccolo
Journal:  Haematologica       Date:  2019-08-29       Impact factor: 9.941

7.  Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097.

Authors:  Lu Wang; Guo Dai; Jian Yang; Wanrong Wu; Wei Zhang
Journal:  Med Sci Monit       Date:  2018-06-14

8.  Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance.

Authors:  Michela Colombo; Silvia Garavelli; Mara Mazzola; Natalia Platonova; Domenica Giannandrea; Raffaella Colella; Luana Apicella; Marialuigia Lancellotti; Elena Lesma; Silvia Ancona; Maria Teresa Palano; Marzia Barbieri; Elisa Taiana; Elisa Lazzari; Andrea Basile; Mauro Turrini; Anna Pistocchi; Antonino Neri; Raffaella Chiaramonte
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941

9.  Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia.

Authors:  Dan Li; Tongjuan Li; Zhen Shang; Lei Zhao; Qian Xu; Jiaqi Tan; Yun Qin; Yuanyuan Zhang; Yang Cao; Na Wang; Liang Huang; Xiaojian Zhu; Kuangguo Zhou; Liting Chen; Chunrui Li; Ting Xie; Yi Yang; Jue Wang; Jianfeng Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-03-13

10.  Jagged Ligands Enhance the Pro-Angiogenic Activity of Multiple Myeloma Cells.

Authors:  Maria Teresa Palano; Domenica Giannandrea; Natalia Platonova; Germano Gaudenzi; Monica Falleni; Delfina Tosi; Elena Lesma; Valentina Citro; Michela Colombo; Ilaria Saltarella; Roberto Ria; Nicola Amodio; Elisa Taiana; Antonino Neri; Giovanni Vitale; Raffaella Chiaramonte
Journal:  Cancers (Basel)       Date:  2020-09-11       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.